All drugs
CRB-913
Stage Phase 1Stale
Sponsor Corbus Pharmaceuticals Inc.
Sources
registry, as of 2026-10-09Stale
https://clinicaltrials.gov/study/NCT07310901
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Corbus Pharmaceuticals Inc.. Enrollment 254. Conditions Obese But Otherwise Healthy Participants. This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to eval
ClinicalTrials.gov NCT07310901 protocol and results modules
Studies
Registry NCT07310901
Phase Phase 1
Status Completed
Enrollment 254
Start 2025-12-04
Primary completion 2026-08-03
Study completion 2026-08-03
Catalyst Primary completion. 2026-08-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale
Part 1: PK Lead-in
Comparator placebo
Population Obese But Otherwise Healthy Participants
Part 2: CRB-913 low dose
Comparator placebo
Population Obese But Otherwise Healthy Participants
Part 2: CRB-913 Medium Dose
Comparator placebo
Population Obese But Otherwise Healthy Participants
Part 2: CRB-913 High Dose
Comparator placebo
Population Obese But Otherwise Healthy Participants
Part 2: Placebo
Population Obese But Otherwise Healthy Participants